Last $51.51 USD
Change Today +0.39 / 0.76%
Volume 7.1M
BMY On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Frankfurt
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$51.44
Previous Close
$51.12
Day High
$51.77
Day Low
$51.38
52 Week High
03/6/14 - $57.49
52 Week Low
09/30/13 - $45.70
Market Cap
85.4B
Average Volume 10 Days
5.1M
EPS TTM
$1.78
Shares Outstanding
1.7B
EX-Date
10/1/14
P/E TM
28.9x
Dividend
$1.44
Dividend Yield
2.78%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances and collaborations with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $901.1K
Chief Operating Officer and Director
Total Annual Compensation: $748.3K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $736.1K
General Counsel and Corporate Secretary
Total Annual Compensation: $843.1K
Compensation as of Fiscal Year 2013.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock, Payable on November 3, 2014 and on Preferred Stock Payable on December 1, 2014

The board of directors of Bristol-Myers Squibb Company declared a quarterly dividend of 36 cents ($0.36) per share on the $0.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 3, 2014, to stockholders of record at the close of business on October 3, 2014. The directors also declared a quarterly dividend of 50 cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable on December 1, 2014 to stockholders of record at the close of business on November 7, 2014.

Bristol-Myers Squibb Company Announces Health Canada Has Approves Yervoy (Ipilimumab) as First-Line Therapy in Adults with Unresectable or Metastatic Melanoma

Bristol-Myers Squibb Company announced that Health Canada has approved Yervoy (ipilimumab) as a first-line therapy in adults with unresectable or metastatic melanoma, the most deadly form of skin cancer. This means that Canadians with newly diagnosed advanced melanoma, regardless of the subtype, will be eligible to receive the novel immunotherapy as their initial treatment. Unlike traditional therapies that target the tumour directly, immuno-oncology is an innovative field of cancer research and treatment focused on harnessing the power of the body's immune system to fight cancer. Such treatments target the very same pathways tumour cells use to evade recognition and destruction. Yervoy specifically blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), which plays a role in suppressing the normal immune response. Yervoy blocks that suppression to allow the immune system to respond to melanoma cancer cells.

Bristol-Myers Squibb Company Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 09:45 AM

Bristol-Myers Squibb Company Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 09:45 AM. Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom. Speakers: John E. Elicker, Senior Vice President of Public Affairs and Investor Relations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $51.51 USD +0.39

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.06 USD -0.39
Actavis plc $241.81 USD +3.88
Celgene Corp $93.85 USD +0.58
Novo Nordisk A/S kr281.70 DKK +0.10
Thermo Fisher Scientific Inc $123.24 USD -0.89
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 31.7x
Price/Sales 5.2x
Price/Book 5.5x
Price/Cash Flow 31.5x
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.